1061 related articles for article (PubMed ID: 16304150)
1. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
2. Combined antifungal therapy in a murine infection by Candida glabrata.
Mariné M; Serena C; Pastor FJ; Guarro J
J Antimicrob Chemother; 2006 Dec; 58(6):1295-8. PubMed ID: 17012301
[TBL] [Abstract][Full Text] [Related]
3. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata.
Mariné M; Serena C; Fernández-Torres B; Pastor FJ; Guarro J
Antimicrob Agents Chemother; 2005 Nov; 49(11):4757-9. PubMed ID: 16251323
[TBL] [Abstract][Full Text] [Related]
4. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.
Graybill JR; Bocanegra R; Gonzalez GM; Najvar LK
J Antimicrob Chemother; 2003 Oct; 52(4):656-62. PubMed ID: 12972452
[TBL] [Abstract][Full Text] [Related]
5. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
[TBL] [Abstract][Full Text] [Related]
6. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
Clemons KV; Espiritu M; Parmar R; Stevens DA
Antimicrob Agents Chemother; 2005 Dec; 49(12):4867-75. PubMed ID: 16304147
[TBL] [Abstract][Full Text] [Related]
8. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis.
Adler-Moore JP; Olson JA; Proffitt RT
J Antimicrob Chemother; 2004 Dec; 54(6):1096-102. PubMed ID: 15509617
[TBL] [Abstract][Full Text] [Related]
9. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.
Shorr AF; Wu C; Kothari S
J Antimicrob Chemother; 2011 Feb; 66(2):375-80. PubMed ID: 21147825
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
de Wet N; Llanos-Cuentas A; Suleiman J; Baraldi E; Krantz EF; Della Negra M; Diekmann-Berndt H
Clin Infect Dis; 2004 Sep; 39(6):842-9. PubMed ID: 15472817
[TBL] [Abstract][Full Text] [Related]
11. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
Gumbo T; Drusano GL; Liu W; Kulawy RW; Fregeau C; Hsu V; Louie A
Antimicrob Agents Chemother; 2007 Mar; 51(3):968-74. PubMed ID: 17194830
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model.
Nagasaki Y; Eriguchi Y; Uchida Y; Miyake N; Maehara Y; Kadowaki M; Harada M; Akashi K; Shimono N
J Antimicrob Chemother; 2009 Aug; 64(2):379-82. PubMed ID: 19465436
[TBL] [Abstract][Full Text] [Related]
13. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
15. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
16. Micafungin: a new echinocandin.
Chandrasekar PH; Sobel JD
Clin Infect Dis; 2006 Apr; 42(8):1171-8. PubMed ID: 16575738
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice.
Ninomiya M; Mikamo H; Tanaka K; Watanabe K; Tamaya T
J Antimicrob Chemother; 2005 Apr; 55(4):587-90. PubMed ID: 15728144
[TBL] [Abstract][Full Text] [Related]
18. The echinocandins.
Cappelletty D; Eiselstein-McKitrick K
Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
[TBL] [Abstract][Full Text] [Related]
19. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
[TBL] [Abstract][Full Text] [Related]
20. [Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
Rome A; André N; Michel A; Coze C; Gentet JC; Bernard JL
Arch Pediatr; 2006 Dec; 13(12):1556-7. PubMed ID: 17049216
[No Abstract] [Full Text] [Related]
[Next] [New Search]
